A consortium of investors led a $315m funding round in Prime Medicine, a developer of novel gene-editing technology solutions. Investors in the round include ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital and T. Rowe Price Associates. "Prime Editing represents an opportunity to do what no gene editing approach has yet been capable of – correcting nearly all types of pathogenic gene mutations, correcting multiple mutations at once, and bringing durable cures to patients across multiple disease areas, potentially with a single 'once and done' treatment approach. We are tremendously excited about the potential of this technology, and about the talented team at Prime working to bring it to patients," David Schenkein, GV General Partner.